Send to

Choose Destination
Vaccine. 2015 Feb 11;33(7):933-41. doi: 10.1016/j.vaccine.2014.08.027. Epub 2014 Aug 21.

Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy.

Author information

Palmetto Pediatrics, 2781 Tricom St, North Charleston, SC 29406, United States. Electronic address:
ACC Pediatric Research, Oak Thicket Shopping Center, 1025 Highway 80 East Haughton, Bossier City, LA 71037, United States.
Division of General Academic Pediatrics, University of Texas Medical Branch at Galveston, 301 University Blvd, Galveston, TX 77555, United States.
Baptist Health Lexington, 1740 Nicholasville Road, Lexington, KY 40503, United States.
Dixie Pediatrics, 1240 E 100 S Suite 14, Saint George, UT 84790, United States.
Jordan Valley Medical Center, 3580 West 9000 South, West Jordan, UT 84088, United States.
30 E Hickman Road, Waukee, IA 50263, United States.
Saint Clair Hospital, 1000 Bower Hill Road, Pittsburgh, PA 15243, United States.
GlaxoSmithKline Vaccines, Rue Fleming 20, Wavre 1300, Belgium.
GlaxoSmithKline Vaccines, 2301 Renaissance Blvd, RN0220, King of Prussia, PA 19406, United States.



Immunogenicity and safety of a single dose of MenACWY-TT or a fourth dose of HibMenCY-TT were evaluated in the second year of life in HibMenCY-TT-primed toddlers.


Healthy infants were randomized (5:1) and primed at 2, 4 and 6 months of age with HibMenCY-TT and diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus (DTaP-HBV-IPV) vaccine; or Hib-TT and DTaP-HBV-IPV (control). Recipients of HibMenCY-TT+DTaP-HBV-IPV were re-randomized (2:2:1) to receive MenACWY-TT at 12-15 months and DTaP at 15-18 months; MenACWY-TT co-administered with DTaP at 15-18 months; or HibMenCY-TT at 12-15 months and DTaP at 15-18 months. Controls received DTaP only at 15-18 months due to Hib conjugate vaccine shortage. Serum bactericidal activity using human complement (hSBA) and safety were assessed one month after meningococcal vaccination.


After vaccination with MenACWY-TT at 12-15 months or MenACWY-TT+DTaP at 15-18 months, all subjects previously primed for serogroups C/Y had hSBA ≥1:8 for these serogroups. At least 96.1% also had hSBA ≥1:8 for serogroups A/W. All subjects in the HibMenCY-TT group had hSBA ≥1:8 for serogroups C/Y. All pre-defined statistical criteria for meningococcal immunogenicity were satisfied. All vaccination regimens had acceptable safety profiles.


Children primed with three doses of HibMenCY-TT who then received a single dose of MenACWY-TT or a fourth dose of HibMenCY-TT had robust increases in hSBA titers for serogroups C/Y. These data provide support that MenACWY-TT, given with or without the fourth scheduled dose of DTaP could be administered as an alternative to a fourth dose of HibMenCY-TT in the second year of life. This study (110870/110871) is registered at NCT00614614.


ACWY; Conjugate vaccine; HibMenCY; Quadrivalent meningococcal vaccine; Serum bactericidal activity

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center